Cargando…

A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer

BACKGROUND: Gastric cancer (GC) is the third leading cause of cancer death worldwide with complicated molecular and cellular heterogeneity. Iron metabolism and ferroptosis play crucial roles in the pathogenesis of GC. However, the prognostic role and immunotherapy biomarker potential of ferroptosis-...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shi-jin, Yang, Ya-bing, Zhou, Jia-xin, Lin, Yu-jian, Pan, Yun-long, Pan, Jing-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642032/
https://www.ncbi.nlm.nih.gov/pubmed/34868391
http://dx.doi.org/10.1155/2021/2385406
_version_ 1784609607242481664
author Liu, Shi-jin
Yang, Ya-bing
Zhou, Jia-xin
Lin, Yu-jian
Pan, Yun-long
Pan, Jing-hua
author_facet Liu, Shi-jin
Yang, Ya-bing
Zhou, Jia-xin
Lin, Yu-jian
Pan, Yun-long
Pan, Jing-hua
author_sort Liu, Shi-jin
collection PubMed
description BACKGROUND: Gastric cancer (GC) is the third leading cause of cancer death worldwide with complicated molecular and cellular heterogeneity. Iron metabolism and ferroptosis play crucial roles in the pathogenesis of GC. However, the prognostic role and immunotherapy biomarker potential of ferroptosis-related genes (FRGs) in GC still remains to be clarified. METHODS: We comprehensively analyzed the prognosis of different expression FRGs, based on gastric carcinoma patients in the TCGA cohort. The functional enrichment and immune microenvironment associated with these genes in gastric cancer were investigated. The prognostic model was constructed to clarify the relation between FRGs and the prognosis of GC. Meanwhile, the ceRNA network of FRGs in the prognostic model was performed to explore the regulatory mechanisms. RESULTS: Gastric carcinoma patients were classified into the A, B, and C FRGClusters with different features based on 19 prognostic ferroptosis-related differentially expressed genes in the TCGA database. To quantify the FRG characteristics of individual patients, FRGScore was constructed. And the research shows the GC patients with higher FRGScore had worse survival outcome. Moreover, thirteen prognostic ferroptosis-related differentially expressed genes (DEGs) were selected to construct a prognostic model for GC survival outcome with a superior accuracy in this research. And we also found that FRG RiskScore can be an independent biomarker for the prognosis of GC patients. Interestingly, GC patients with lower RiskScore had less immune dysfunction and were more likely to respond to immunotherapy according to TIDE value analysis. Finally, a ceRNA network based on FRGs in the prognostic model was analyzed to show the concrete regulation mechanisms. CONCLUSIONS: The ferroptosis-related gene risk signature has a superior potent in predicting GC prognosis and acts as the biomarkers for immunotherapy, which may provide a reference in clinic.
format Online
Article
Text
id pubmed-8642032
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86420322021-12-04 A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer Liu, Shi-jin Yang, Ya-bing Zhou, Jia-xin Lin, Yu-jian Pan, Yun-long Pan, Jing-hua Dis Markers Research Article BACKGROUND: Gastric cancer (GC) is the third leading cause of cancer death worldwide with complicated molecular and cellular heterogeneity. Iron metabolism and ferroptosis play crucial roles in the pathogenesis of GC. However, the prognostic role and immunotherapy biomarker potential of ferroptosis-related genes (FRGs) in GC still remains to be clarified. METHODS: We comprehensively analyzed the prognosis of different expression FRGs, based on gastric carcinoma patients in the TCGA cohort. The functional enrichment and immune microenvironment associated with these genes in gastric cancer were investigated. The prognostic model was constructed to clarify the relation between FRGs and the prognosis of GC. Meanwhile, the ceRNA network of FRGs in the prognostic model was performed to explore the regulatory mechanisms. RESULTS: Gastric carcinoma patients were classified into the A, B, and C FRGClusters with different features based on 19 prognostic ferroptosis-related differentially expressed genes in the TCGA database. To quantify the FRG characteristics of individual patients, FRGScore was constructed. And the research shows the GC patients with higher FRGScore had worse survival outcome. Moreover, thirteen prognostic ferroptosis-related differentially expressed genes (DEGs) were selected to construct a prognostic model for GC survival outcome with a superior accuracy in this research. And we also found that FRG RiskScore can be an independent biomarker for the prognosis of GC patients. Interestingly, GC patients with lower RiskScore had less immune dysfunction and were more likely to respond to immunotherapy according to TIDE value analysis. Finally, a ceRNA network based on FRGs in the prognostic model was analyzed to show the concrete regulation mechanisms. CONCLUSIONS: The ferroptosis-related gene risk signature has a superior potent in predicting GC prognosis and acts as the biomarkers for immunotherapy, which may provide a reference in clinic. Hindawi 2021-11-26 /pmc/articles/PMC8642032/ /pubmed/34868391 http://dx.doi.org/10.1155/2021/2385406 Text en Copyright © 2021 Shi-jin Liu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liu, Shi-jin
Yang, Ya-bing
Zhou, Jia-xin
Lin, Yu-jian
Pan, Yun-long
Pan, Jing-hua
A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer
title A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer
title_full A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer
title_fullStr A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer
title_full_unstemmed A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer
title_short A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer
title_sort novel ferroptosis-related gene risk signature for predicting prognosis and immunotherapy response in gastric cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642032/
https://www.ncbi.nlm.nih.gov/pubmed/34868391
http://dx.doi.org/10.1155/2021/2385406
work_keys_str_mv AT liushijin anovelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT yangyabing anovelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT zhoujiaxin anovelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT linyujian anovelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT panyunlong anovelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT panjinghua anovelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT liushijin novelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT yangyabing novelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT zhoujiaxin novelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT linyujian novelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT panyunlong novelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer
AT panjinghua novelferroptosisrelatedgenerisksignatureforpredictingprognosisandimmunotherapyresponseingastriccancer